论文部分内容阅读
报道恶性脑瘤手术后临床应用VM_(26)—CCNU序列化疗18例46个疗程的初步经验。每一个疗程先用VM_(26)60mg/m~2/日静脉滴注连用二天,继以CCNU80mg/日口服连服二天。每间隔6周重复用药一次。VM_(26)—CCNu两者合用能起协同作用,降低各自的用量,减少副作用,提高疗效,使多疗程治疗得以顺利继续。本组初步经验提示VM_(26)具有安全、毒性低、副作用少、骨髓抑制不明显、抗瘤谱广等优点,对室管膜瘤的效用尤为明显。
Reported the preliminary experience of the clinical application of VM_(26)—CCNU sequence chemotherapy in 18 cases of malignant brain tumor after surgery. Each course of treatment was firstly intravenously administered with VM_(26) 60 mg/m~2/day for 2 days, followed by oral administration of CCNU 80 mg/day for 2 days. Repeat dosing every 6 weeks. The combination of VM_(26) and CCNu can synergistically reduce their respective dosages, reduce side effects and improve efficacy, so that multiple courses of treatment can be continued smoothly. The preliminary experience of this group suggests that VM_(26) has the advantages of safety, low toxicity, few side effects, insignificant bone marrow suppression, and broad spectrum of tumor resistance, and is particularly effective for ependymoma.